Tyrosine kinase inhibitor–induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling

Abstract excerpt

In chronic myelogenous leukemia (CML), oncogenic BCR-ABL1 activates the Wnt pathway, which is fundamental for leukemia stem cell (LSC) maintenance. Tyrosine kinase inhibitor (TKI) treatment reduces Wnt signaling in LSCs and often results in molecular remission of CML; however, LSCs persist long term despite BCR-ABL1 inhibition, ultimately causing disease relapse. We demonstrate that TKIs induce the expression of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Myeloid Leukemia Treatments
• Share to Fibroblast Growth Factor Research
• Share to Wnt/β-catenin signaling in development and cancer